The Landscape and Prognosis of Microsatellite Stable (MSS) Esophageal, Gastro-Esophageal Junction and Gastric Adenocarcinomas with High Tumor Mutation Burden (TMB)

References

• Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–542. PMID: 31362118; PMCID: PMC8859863. doi:10.1016/j.cgh.2019.07.045.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, ToGA Trial Investigators, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X.PMID: 20728210.
   PubMed Web of Science ®Google Scholar
• Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942–948. PMID: 35322232; PMCID: PMC8967713. doi:10.1038/s41586-022-04508-4.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–730. PMID: 34912120; PMCID: PMC8959470. doi:10.1038/s41586-021-04161-3.
   PubMed Web of Science ®Google Scholar
• Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, DESTINY-Gastric01 Investigators, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–2430. PMID: 32469182. doi:10.1056/NEJMoa2004413.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi:10.1016/S1470-2045(20)30445-9.PMID: 32919526.
   PubMed Web of Science ®Google Scholar
• Lee KW, Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I, Garrido M, et al. Association of tumor mutational burden with efficacy of pembrolizumab ± chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study. Clin Cancer Res. 2022;28(16):3489–3498. PMID: 35657979. doi:10.1158/1078-0432.CCR-22-0121.
   PubMed Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol. 2021;32(9):1127–1136. PMID: 34082019. doi:10.1016/j.annonc.2021.05.803.
   PubMed Web of Science ®Google Scholar
• Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 2019;24(1):103–109. PMID: 30120163; PMCID: PMC6324629. doi:10.1634/theoncologist.2018-0221.
   PubMed Web of Science ®Google Scholar
• Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–337. PMID: 30028179. doi:10.5858/arpa.2018-0043-OA.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. PMID: 29543932; PMCID: PMC5885175. doi:10.1001/jamaoncol.2018.0013.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209. PMID: 25079317; PMCID: PMC4170219. doi:10.1038/nature13480.
   PubMed Web of Science ®Google Scholar
• Sihag S, Nussenzweig SC, Walch HS, Hsu M, Tan KS, Sanchez-Vega F, et al. Next-generation sequencing of 487 esophageal adenocarcinomas reveals independently prognostic genomic driver alterations and pathways. Clin Cancer Res. 2021;27(12):3491–3498. PMID: 33795256; PMCID: PMC8228505. doi:10.1158/1078-0432.CCR-20-4707.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. PMID: 22588877; PMCID: PMC3956037. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. PMID: 23550210; PMCID: PMC4160307. doi:10.1126/scisignal.2004088.
   PubMed Web of Science ®Google Scholar
• Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12(1):323. PMID: 21816040; PMCID: PMC3163565. doi:10.1186/1471-2105-12-323.
   PubMed Web of Science ®Google Scholar
• Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251–264. PMID: 25801821; PMCID: PMC5808190. doi:10.1016/j.jmoldx.2014.12.006.
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017. PO.17.00011. PMID: 28890946; PMCID: PMC5586540. doi:10.1200/PO.17.00011.
   Google Scholar
• Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F, et al. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol. 2023;24(2):151–161. doi:10.1016/S1470-2045(22)00783-5. PMID: 36681091; PMCID: PMC10599647.
   PubMed Web of Science ®Google Scholar
• Stachler MD, Jin RU. Molecular pathology of gastroesophageal cancer. Surg Pathol Clin. 2021;14(3):443–453. PMID: 34373095. doi:10.1016/j.path.2021.05.008.
   PubMedGoogle Scholar
• Li JJ, Rogers JE, Yamashita K, Waters RE, Blum Murphy M, Ajani JA. Therapeutic advances in the treatment of gastroesophageal cancers. Biomolecules. 2023;13(5):796. PMID: 37238666; PMCID: PMC10216443. doi:10.3390/biom13050796.
   PubMed Web of Science ®Google Scholar
• Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133–2141. PMID: 37524953; PMCID: PMC10427418. doi:10.1038/s41591-023-02465-7.
   PubMed Web of Science ®Google Scholar
• Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018;6(1):35. PMID: 29754585; PMCID: PMC5950135. doi:10.1186/s40425-018-0342-x.
   PubMedGoogle Scholar
• Voutsadakis IA. Polymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer. Gene. 2018;647:31–38. PMID: 29320758. doi:10.1016/j.gene.2018.01.030.
   PubMed Web of Science ®Google Scholar
• Wang JY, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, et al. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. Ann Oncol. 2021;32(7):906–916. PMID: 33798656. doi:10.1016/j.annonc.2021.03.203.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. The landscape of PIK3CA mutations in colorectal cancer. Clin Colorectal Cancer. 2021;20(3):201–215. PMID: 33744168. doi:10.1016/j.clcc.2021.02.003.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. The genomic environment of BRAF mutated and BRAF/PIK3CA double mutated colorectal cancers. J Clin Med. 2022;11(17):5132. PMID: 36079062; PMCID: PMC9456575. doi:10.3390/jcm11175132.
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Xiu J, Goldberg RM, Philip PA, Seeber A, Battaglin F, et al. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Eur J Cancer. 2020;140:119–129. PMID: 33080474; PMCID: PMC8009046. doi:10.1016/j.ejca.2020.09.006.
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: diverse molecular associations point to variable pathophysiology. Cancer Treat Res Commun. 2023;36:100746. PMID: 37494750. doi:10.1016/j.ctarc.2023.100746.
   PubMedGoogle Scholar
• Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, et al. Association of homologous recombination-DNA damage response gene mutations with immune biomarkers in gastroesophageal cancers. Mol Cancer Ther. 2022;21(1):227–236. PMID: 34725190; PMCID: PMC9506445. doi:10.1158/1535-7163.MCT-20-0879.
   PubMed Web of Science ®Google Scholar
• Harrod A, Lane KA, Downs JA. The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks. DNA Repair (Amst). 2020;93:102919. PMID: 33087260. doi:10.1016/j.dnarep.2020.102919.
   PubMed Web of Science ®Google Scholar
• Botta GP, Kato S, Patel H, Fanta P, Lee S, Okamura R, Kurzrock R. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. JCI Insight. 2021;6(18):e150453. PMID: 34375311; PMCID: PMC8492298. doi:10.1172/jci.insight.150453.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yan C, Wang X, Xu Z, Lv J, Xu X, et al. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy. Cancer Biol Ther. 2022;23(1):104–111. PMID: 35239432; PMCID: PMC8896200. doi:10.1080/15384047.2021.2011643.
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol. 2022;33(11):1204–1206. PMID: 35926816; PMCID: PMC10325933. doi:10.1016/j.annonc.2022.07.009.
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–672. PMID: 33736924; PMCID: PMC8053682. doi:10.1016/j.annonc.2021.02.006.
   PubMed Web of Science ®Google Scholar